Literature DB >> 23208718

HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.

P Recordon-Pinson1, S Raymond, P Bellecave, A G Marcelin, C Soulie, D Descamps, V Calvez, P R Harrigan, H Fleury, J Izopet, B Masquelier.   

Abstract

There is evidence that HIV-1 evolution under maraviroc (MVC) pressure can lead to the selection of either X4-tropic variants and/or R5-tropic, MVC-resistant isolates. However, the viral dynamics of HIV-1 variants in patients with virological failure (VF) on MVC-containing regimens remain poorly studied. Here, we investigated the V3 loop evolution of HIV-1 on MVC in relation to coreceptor usage and the nature of HIV-1 quasispecies before MVC therapy using bulk population sequences and ultradeep sequencing. The majority of patients had no detectable minority X4 variant at baseline. The evolution of tropism was followed up until VF and showed three possibilities for viral evolution in these patients: emergence of preexisting X4 variants, de novo selection of R5 variants presenting V3 loop mutations, or replication of R5 variants without selection of known mutations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23208718      PMCID: PMC3553713          DOI: 10.1128/AAC.02159-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.

Authors:  Patricia Recordon-Pinson; Cathia Soulié; Philippe Flandre; Diane Descamps; Mouna Lazrek; Charlotte Charpentier; Brigitte Montes; Mary-Anne Trabaud; Jacqueline Cottalorda; Véronique Schneider; Laurence Morand-Joubert; Catherine Tamalet; Delphine Desbois; Muriel Macé; Virginie Ferré; Astrid Vabret; Annick Ruffault; Coralie Pallier; Stéphanie Raymond; Jacques Izopet; Jacques Reynes; Anne-Geneviève Marcelin; Bernard Masquelier
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

Review 2.  Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.

Authors:  Rodger D MacArthur; Richard M Novak
Journal:  Clin Infect Dis       Date:  2008-07-15       Impact factor: 9.079

3.  Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage.

Authors:  Stéphanie Raymond; Pierre Delobel; Maud Mavigner; Michelle Cazabat; Corinne Souyris; Stéphanie Encinas; Patrick Bruel; Karine Sandres-Sauné; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  J Clin Virol       Date:  2009-12-16       Impact factor: 3.168

4.  Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Authors:  Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

5.  A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.

Authors:  John C Tilton; Craig B Wilen; Chukwuka A Didigu; Rohini Sinha; Jessamina E Harrison; Caroline Agrawal-Gamse; Elizabeth A Henning; Frederick D Bushman; Jeffrey N Martin; Steven G Deeks; Robert W Doms
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

6.  An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence.

Authors:  Brian M Taylor; J Scott Foulke; Robin Flinko; Alonso Heredia; Anthony DeVico; Marvin Reitz
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

7.  Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

Authors:  Zhaohui Su; Roy M Gulick; Amy Krambrink; Eoin Coakley; Michael D Hughes; Dong Han; Charles Flexner; Timothy J Wilkin; Paul R Skolnik; Wayne L Greaves; Daniel R Kuritzkes; Jacqueline D Reeves
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

8.  Maraviroc for previously treated patients with R5 HIV-1 infection.

Authors:  Roy M Gulick; Jacob Lalezari; James Goodrich; Nathan Clumeck; Edwin DeJesus; Andrzej Horban; Jeffrey Nadler; Bonaventura Clotet; Anders Karlsson; Michael Wohlfeiler; John B Montana; Mary McHale; John Sullivan; Caroline Ridgway; Steve Felstead; Michael W Dunne; Elna van der Ryst; Howard Mayer
Journal:  N Engl J Med       Date:  2008-10-02       Impact factor: 91.245

Review 9.  A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.

Authors:  John P Moore; Daniel R Kuritzkes
Journal:  Curr Opin HIV AIDS       Date:  2009-03       Impact factor: 4.283

Review 10.  HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV.

Authors:  Claudia Cicala; James Arthos; Anthony S Fauci
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

View more
  9 in total

1.  Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.

Authors:  A Gonzalez-Serna; M Genebat; M De Luna-Romero; L Tarancon-Diez; B Dominguez-Molina; Y M Pacheco; M A Muñoz-Fernández; M Leal; E Ruiz-Mateos
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  A deep sequencing reveals significant diversity among dominant variants and evolutionary dynamics of avian leukosis viruses in two infectious ecosystems.

Authors:  Fanfeng Meng; Xuan Dong; Tao Hu; Shuang Chang; Jianhua Fan; Peng Zhao; Zhizhong Cui
Journal:  BMC Vet Res       Date:  2016-12-19       Impact factor: 2.741

Review 3.  Deep sequencing: becoming a critical tool in clinical virology.

Authors:  Miguel E Quiñones-Mateu; Santiago Avila; Gustavo Reyes-Teran; Miguel A Martinez
Journal:  J Clin Virol       Date:  2014-06-24       Impact factor: 3.168

4.  Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.

Authors:  Takeo Kuwata; Ikumi Enomoto; Masanori Baba; Shuzo Matsushita
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

5.  A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251.

Authors:  Koen K A Van Rompay; Zoe Hunter; Kartika Jayashankar; Julianne Peabody; David Montefiori; Celia C LaBranche; Brandon F Keele; Kara Jensen; Kristina Abel; Bryce Chackerian
Journal:  J Virol       Date:  2013-12-04       Impact factor: 5.103

6.  A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.

Authors:  Javier Garcia-Perez; Isabelle Staropoli; Stéphane Azoulay; Jean-Thomas Heinrich; Almudena Cascajero; Philippe Colin; Hugues Lortat-Jacob; Fernando Arenzana-Seisdedos; Jose Alcami; Esther Kellenberger; Bernard Lagane
Journal:  Retrovirology       Date:  2015-06-18       Impact factor: 4.602

7.  In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells.

Authors:  Masaru Yokoyama; Masako Nomaguchi; Naoya Doi; Tadahito Kanda; Akio Adachi; Hironori Sato
Journal:  Front Microbiol       Date:  2016-02-09       Impact factor: 5.640

8.  Dynamic Co-evolution and Interaction of Avian Leukosis Virus Genetic Variants and Host Immune Responses.

Authors:  Xuan Dong; Fanfeng Meng; Tao Hu; Sidi Ju; Yang Li; Peng Sun; Yixin Wang; Wenqing Chen; Fushou Zhang; Hongqin Su; Sifei Li; He Cui; Junxia Chen; Shuzhen Xu; Lichun Fang; Huaibiao Luan; Zhenjie Zhang; Shuang Chang; Jianliang Li; Lei Wang; Peng Zhao; Weifeng Shi; Zhizhong Cui
Journal:  Front Microbiol       Date:  2017-06-26       Impact factor: 5.640

9.  Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients.

Authors:  Alejandro Gonzalez-Serna; Miguel Genebat; Ezequiel Ruiz-Mateos; Manuel Leal
Journal:  Drug Des Devel Ther       Date:  2016-01-18       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.